IE
CRSP icon

Israel Englander’s CRISPR Therapeutics CRSP Stock Holding History

Israel Englander’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15M Buy
+57,700
New +$3.04M ﹤0.01% 3421
2024
Q4 		– Sell
-33,000
Closed -$1.55M – 6030
2024
Q3 		$1.55M Buy
+33,000
New +$1.67M ﹤0.01% 3932
2024
Q2 		– Sell
-3,100
Closed -$211K – 5980
2024
Q1 		$211K Buy
+3,100
New +$222K ﹤0.01% 5346
2023
Q3 		– Sell
-50,500
Closed -$2.84M – 6187
2023
Q2 		$2.84M Buy
50,500
+20,500
+68% +$1.16M ﹤0.01% 3180
2023
Q1 		$1.36M Buy
+30,000
New +$1.46M ﹤0.01% 3803
2022
Q3 		– Sell
-20,000
Closed -$1.22M – 7125
2022
Q2 		$1.22M Sell
20,000
-1,400
-7% -$82.3K ﹤0.01% 4201
2022
Q1 		$1.34M Sell
21,400
-6,100
-22% -$383K ﹤0.01% 4248
2021
Q4 		$2.08M Sell
27,500
-2,500
-8% -$218K ﹤0.01% 3743
2021
Q3 		$3.36M Buy
30,000
+5,100
+20% +$641K ﹤0.01% 3333
2021
Q2 		$4.03M Buy
24,900
+2,400
+11% +$292K ﹤0.01% 3046
2021
Q1 		$2.74M Sell
22,500
-17,500
-44% -$2.64M ﹤0.01% 3224
2020
Q4 		$6.12M Buy
+40,000
New +$4.73M ﹤0.01% 2245
2020
Q3 		– Sell
-25,000
Closed -$1.84M – 4503
2020
Q2 		$1.84M Buy
+25,000
New +$1.46M ﹤0.01% 2600

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Israel Englander's CRSP Position: Q2 2026 in Review

Israel Englander increased its CRISPR Therapeutics (CRSP) stake by 1.3% in Q2 2026, buying an estimated $256K and bringing the position to 382,032 shares worth $20.8M. The position accounts for 0.01% of the portfolio, ranked #1587.

Israel Englander first reported a position in CRSP in Q4 2016 and has held it in 30 quarters since. The position peaked at $29.2M in Q4 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Israel Englander held 382,032 shares of CRISPR Therapeutics worth $20.8M as of Q2 2026.
  • Israel Englander bought 4,854 CRISPR Therapeutics shares in Q2 2026, an estimated $256K.
  • CRISPR Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1587 holding.
  • Israel Englander first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 30 quarters since.
  • Israel Englander's CRISPR Therapeutics position peaked at $29.2M in Q4 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.